| Title |
Profile of a fixed-dose combination of tiotropium/olodaterol and its potential in the treatment of COPD
|
|---|---|
| Published in |
International Journal of Chronic Obstructive Pulmonary Disease, June 2015
|
| DOI | 10.2147/copd.s54154 |
| Pubmed ID | |
| Authors |
Sanjeevan Muruganandan, Lata Jayaram |
| Abstract |
Chronic obstructive pulmonary disease (COPD) is a progressive, debilitating disorder that results in frequent exacerbations and impacts quality of life. It represents a growing burden of health care cost, both from societal and economic perspectives. Short- and long-acting bronchodilators remain the mainstay of therapy in COPD patients. New fixed-dose combination inhalers with novel pharmacological combinations of long-acting β2-agonists and muscarinic antagonists and delivered once-daily through a variety of devices are currently being developed and licensed for the treatment of COPD. There is mounting research suggesting that combining a fixed dose of a β2-agonist and a muscarinic antagonist achieves better bronchodilation and clinical outcomes compared with either agent alone. These once-daily dosing inhalers are anticipated to impact favorably on patient preference and compliance. This review examines the fixed-dose combination of tiotropium bromide and olodaterol delivered by a Respimat(®) Soft Mist™ inhaler at doses of 2.5/5 μg and 5/5 μg in moderate-to-very-severe COPD, and its potential role in COPD compared with other long-acting β2-agonist with long-acting muscarinic antagonist combinations and delivery devices. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 50 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 50 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 6 | 12% |
| Other | 5 | 10% |
| Student > Ph. D. Student | 5 | 10% |
| Student > Postgraduate | 5 | 10% |
| Student > Master | 5 | 10% |
| Other | 11 | 22% |
| Unknown | 13 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 22 | 44% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 10% |
| Biochemistry, Genetics and Molecular Biology | 3 | 6% |
| Nursing and Health Professions | 2 | 4% |
| Economics, Econometrics and Finance | 2 | 4% |
| Other | 3 | 6% |
| Unknown | 13 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 June 2015.
All research outputs
#20,656,820
of 25,374,647 outputs
Outputs from International Journal of Chronic Obstructive Pulmonary Disease
#2,078
of 2,577 outputs
Outputs of similar age
#206,510
of 281,411 outputs
Outputs of similar age from International Journal of Chronic Obstructive Pulmonary Disease
#54
of 71 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,577 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.5. This one is in the 6th percentile – i.e., 6% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 281,411 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 71 others from the same source and published within six weeks on either side of this one. This one is in the 2nd percentile – i.e., 2% of its contemporaries scored the same or lower than it.